Earnings ·
Scholar Rock Holding Corporation reported a net loss of $109.9 million for the quarter ended June 30, 2026, compared…
SRRKScholar Rock Holding Corp
Scholar Rock Holding Corporation reported a net loss of $109.9 million for the quarter ended June 30, 2026, compared to $110.0 million in the prior year period. The company held cash and marketable securities of $492.1 million as of June 30, 2026, which included $62.8 million in net proceeds from its at-the-market equity program. Apitegromab's Biologics License Application for spinal muscular atrophy remains on track for a potential FDA approval by the September 30, 2026 PDUFA date, with review of a second fill-finish facility progressing and ample commercial supply secured. The company also initiated the Phase 2 FORGE study for facioscapulohumeral muscular dystrophy and continues engagement with the European Medicines Agency regarding its Marketing Authorisation Application. Scholar Rock is a biopharmaceutical company focused on developing treatments for rare neuromuscular diseases.